消息面上，陇神戎发在互动平台表示，截至2025年7月31日，公司股东户数为28，861户，较上期减少 1.05%。此外，公司新药研发进展受到市场关注，布瑞哌唑口溶膜临床试验仍在推进中。 资金方面，8月5日主力资金净流出3871.51万元，占流通市值的1.09%。近五日主力资金累计净流入 1277.98万元。 风险提示：股市有风险，投资需谨慎。 截至2025年8月5日收盘，陇神戎发股价报11.72元，较前一交易日下跌3.06%。当日成交额5.67亿元，换 手率达15.88%。 陇神戎发属于医药生物行业，主营业务为中成药、化学药的研发、生产和销售。公司控股子公司普安制 药开发的改良型新药布瑞哌唑口溶膜目前正在开展临床试验工作。 ...

Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, is currently conducting clinical trials for a modified new drug, Brupiprazole oral film [2] Group 1 - The modified new drug Brupiprazole oral film is under clinical trial [2] - Investors are encouraged to refer to the company's regular reports and announcements for detailed information on new drug development [2]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-052 5.法定代表人：李伟 甘肃陇神戎发药业股份有限公司 关于子公司完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司全资子公司甘肃新丝路产业投资有限公司 （以下简称"新丝路"）因经营工作需要，于近日完成了经营范围的工商变更登 记手续以及章程修订的备案工作，并取得了甘肃省市场监督管理局核准换发的 《营业执照》。 一、新取得的《营业执照》所载具体信息 1.名称：甘肃新丝路产业投资有限公司 2.统一社会信用代码：916200003253962187 3.类型：有限责任公司（非自然人投资或控股的法人独资） 4.住所：甘肃省兰州市榆中县定远镇国防路 10 号陇神戎发质检办公大楼 5- 1、5-2、5-4、5-22、6-11 室 6.注册资本：肆仟万元整 7.成立日期：2015 年 01 月 30 日 8.经营范围：许可项目：第三类医疗器械经营；消毒器械销售；第三类医疗 器械租赁；小食杂；食品销售；酒类经营；城市配送运输服务（不含危险货物） ...

Group 1 - The company has a modified new drug, Bupropion oral film, currently undergoing clinical trials [2] - The company is responding to investor inquiries regarding its innovative drug development pipeline [2] - The company is focused on the future planning of innovative drugs [2]

Core Viewpoint - Longshen Rongfa (300534.SZ) is currently conducting clinical trials for its improved new drug, Brupaprazole oral film, developed by its subsidiary Puan Pharmaceutical [1] Group 1 - The company has provided updates on its new drug development through announcements on March 28 and July 30, 2025, available on the Giant Tide Information Network [1] - Investors are encouraged to refer to the company's regular reports and temporary announcements for detailed information regarding the new drug research and development [1]

Market Performance - The Traditional Chinese Medicine (TCM) sector rose by 0.42% on August 4, with Longshen Rongfa leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in TCM Sector - Longshen Rongfa (300534) closed at 12.09, up 7.18% with a trading volume of 646,800 shares and a turnover of 777 million yuan [1] - Weikang Pharmaceutical (300878) closed at 27.26, up 6.40% with a trading volume of 198,700 shares and a turnover of 513 million yuan [1] - Darentang (600329) closed at 41.20, up 6.30% with a trading volume of 164,600 shares and a turnover of 664 million yuan [1] Top Losers in TCM Sector - Biotech Valley (833266) closed at 12.80, down 8.51% with a trading volume of 215,700 shares and a turnover of 271 million yuan [2] - Datang Pharmaceutical (836433) closed at 8.19, down 4.88% with a trading volume of 204,800 shares and a turnover of 166 million yuan [2] - Huason Pharmaceutical (002907) closed at 20.00, down 3.57% with a trading volume of 390,300 shares and a turnover of 787 million yuan [2] Capital Flow Analysis - The TCM sector experienced a net outflow of 556 million yuan from institutional investors, while retail investors saw a net inflow of 375 million yuan [2] - The net inflow from speculative funds was 181 million yuan [2] Individual Stock Capital Flow - China Resources Sanjiu (000999) had a net inflow of 86.17 million yuan from institutional investors, while retail investors saw a net outflow of 56.84 million yuan [3] - Yabao Pharmaceutical (600351) had a net inflow of 57.28 million yuan from institutional investors, with retail investors experiencing a net outflow of 42.13 million yuan [3] - Tongrentang (600085) had a net inflow of 53.69 million yuan from institutional investors, while retail investors had a net outflow of 58.73 million yuan [3]

陇神戎发涨超10%，奇正藏药此前涨停，粤万年青、新天药业、盘龙药业、佛慈制药等跟涨。 (本文来自第一财经) ...

A股创新药概念股局部反弹，翰宇药业午后直线拉升涨超10%，海辰药业、阳光诺和、广生堂涨超 10%，福源医药、万泽股份涨停，陇神戎发、京新药业、常山药业、舒泰神等跟涨。 ...

每经AI快讯，8月4日，中药股探底回升，陇神戎发一度涨超10%，奇正藏药此前涨停，粤万年青、新天 药业、盘龙药业、佛慈制药等跟涨。 （文章来源：每日经济新闻） ...

Company Performance - As of August 1, 2025, Longshen Rongfa (300534) closed at 11.28 CNY, up 4.16% with a turnover rate of 16.28% and a trading volume of 491,600 shares, amounting to 554 million CNY [1] - The latest quarterly report shows total revenue of 289 million CNY, a year-on-year increase of 13.52%, and a net profit attributable to shareholders of 24.21 million CNY, up 9.18% year-on-year [1] - The company's non-recurring net profit reached 26.92 million CNY, reflecting a year-on-year growth of 26.88% [1] - Financial ratios include a current ratio of 1.430, a quick ratio of 1.160, and a debt-to-asset ratio of 46.50% [1] Capital Flow - On the reporting day, the net inflow of main funds was 34.93 million CNY, accounting for 6.3% of the total transaction amount [1] - Large orders saw a net inflow of 34.64 million CNY, representing 6.25% of the transaction amount, while small orders experienced a net outflow of 62.55 million CNY, which is 11.28% of the transaction amount [1] Company Background - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. was established in 2002 and is located in Lanzhou, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 303.345 million CNY and has made investments in five enterprises, participated in 2,052 bidding projects, and holds 17 trademarks and 46 patents [2]